FATE Q2 2017 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$142M

Q2 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M-0.1% YoY

Gross Profit

-$7M-672.6% margin

Operating Income

-$10M-932.7% margin

Net Income

-$10M-940.1% margin

EPS (Diluted)

$-0.23

QoQ Revenue Growth

-0.1%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$973,000

Balance Sheet

Total Assets

$74M

Total Liabilities

$19M

Stockholders' Equity

$55M

Cash & Equivalents

$31M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$1M	-0.1%
Gross Profit	-$7M	-$6M	-19.9%
Operating Income	-$10M	-$8M	-19.6%
Net Income	-$10M	-$8M	-14.7%